Drugs / ALZN002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05834296 | Jul 2023 → Mar 2028 expected | Alzheimer disease | Alzamend Neuro, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-31 | Alzamend Neuro, Inc. | Regulatory Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type alzamend.com ↗ |
| 2022-09-29 | Alzamend Neuro, Inc. | Regulatory Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type alzamend.com ↗
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its immunotherapy product candidate ALZN002. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALZN002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05834296 ↗ |
| Action | Inhibit | “resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.” NCT05834296 ↗ |
| Modality | Cell therapy | “The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide” NCT05834296 ↗ |